3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell
4
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large-Cell, Anaplastic
3
Lymphoma, Follicular
3
Lymphoma
3
Hodgkin Disease
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoblastic Lymphadenopathy
2
Burkitt Lymphoma
2
Subcutaneous panniculitis-like T-cell lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Fallopian Tube Neoplasms
1
Enteropathy-Associated T-Cell Lymphoma
1
Interventions
Rituximab
45
Cyclophosphamide
32
fludarabine phosphate
28
fludarabine
19
ibrutinib
17
Peripheral Blood Stem Cell Transplantation
17
Lenalidomide
17
venetoclax
13
Mycophenolic Acid
10
Cyclosporine
10
acalabrutinib
9
Whole-Body Irradiation
9
Filgrastim
9
obinutuzumab
7
Bendamustine Hydrochloride
7
Antilymphocyte Serum
7
Radiotherapy
6
Methotrexate
6
Melphalan
6
Prednisone
5
Etoposide
5
Busulfan
5
zanubrutinib
4
pirtobrutinib
4
aldesleukin
4
Vincristine
4
Tacrolimus
4
Indium
4
Immunotherapy, Adoptive
4
Granulocyte Colony-Stimulating Factor
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT01947140
2022-11-23
PDX+Romi
Columbia University
Phase 1/2
Completed
57 enrolled